RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

Autor: Ryan M. Carr, Denis Vorobyev, Terra Lasho, David L. Marks, Ezequiel J. Tolosa, Alexis Vedder, Luciana L. Almada, Andrey Yurcheko, Ismael Padioleau, Bonnie Alver, Giacomo Coltro, Moritz Binder, Stephanie L. Safgren, Isaac Horn, Xiaona You, Eric Solary, Maria E. Balasis, Kurt Berger, James Hiebert, Thomas Witzig, Ajinkya Buradkar, Temeida Graf, Peter Valent, Abhishek A. Mangaonkar, Keith D. Robertson, Matthew T. Howard, Scott H. Kaufmann, Christopher Pin, Martin E. Fernandez-Zapico, Klaus Geissler, Nathalie Droin, Eric Padron, Jing Zhang, Sergey Nikolaev, Mrinal M. Patnaik
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Druh dokumentu: article
ISSN: 2041-1723
DOI: 10.1038/s41467-021-23186-w
Popis: Chronic myelomonocytic leukaemia is classified as proliferative (pCMML) or dysplastic based on the white blood cell counts but biological differences are unclear. Here, the authors show genetic, transcriptomic and epigenomic differences between these two subtypes establishing that pCMML is RAS-pathway driven and that inhibiting RAS-driven PLK1 expression is a viable therapeutic target.
Databáze: Directory of Open Access Journals